2017
DOI: 10.1016/j.jstrokecerebrovasdis.2017.02.012
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacological Treatment of Visuospatial Neglect: A Systematic Review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 13 publications
(4 citation statements)
references
References 65 publications
(185 reference statements)
0
4
0
Order By: Relevance
“…Results in humans have been mixed but, given to the responsive patient populations, this may be a powerful adjunct to physical therapy. Although beyond the scope of this review, there is also evidence that DA-based pharmacotherapy may be beneficial in aphasia (Gill and Leff, 2012 ), hemi-spatial neglect (van der Kemp et al, 2017 ), and poststroke depression (Kohno et al, 2010 ; Delbari et al, 2011 ; Adam et al, 2013 ; Spiegel and Chatterjee, 2014 ; Stanfill et al, 2016 ). Meanwhile, like the findings for DA-based pharmacotherapies in motor recovery, results in these areas are quite mixed.…”
Section: Discussionmentioning
confidence: 99%
“…Results in humans have been mixed but, given to the responsive patient populations, this may be a powerful adjunct to physical therapy. Although beyond the scope of this review, there is also evidence that DA-based pharmacotherapy may be beneficial in aphasia (Gill and Leff, 2012 ), hemi-spatial neglect (van der Kemp et al, 2017 ), and poststroke depression (Kohno et al, 2010 ; Delbari et al, 2011 ; Adam et al, 2013 ; Spiegel and Chatterjee, 2014 ; Stanfill et al, 2016 ). Meanwhile, like the findings for DA-based pharmacotherapies in motor recovery, results in these areas are quite mixed.…”
Section: Discussionmentioning
confidence: 99%
“…Pharmacological interventions continue to be considered for the treatment of inattention, particularly cholinergic therapies, such as rivastigmine [ 65 , 66 ], though there is a marked absence of double-blind, randomized clinical trials. Presently, clinical trials targeting general cognitive improvement are underway using levodopa (NCT03735901) and maraviroc (NCT04966429), and rolflumilast is under investigation specifically for treating post-stroke memory impairment (NCT04854811).…”
Section: Cognition and Memorymentioning
confidence: 99%
“…Other pharmacological approaches include noradrenergic agents (Malhotra, Parton, Greenwood, & Husain, 2006) and pro-cholinergic drugs (Thiel, Zilles, & Fink, 2005). To date, no valid conclusions can be drawn and pharmacological treatment is usually not part of the rehabilitative strategy (van der Kemp, Dorresteijn, Ten Brink, Nijboer, & Visser-Meily, 2017).…”
Section: Therapymentioning
confidence: 99%